Mylan has announced that its subsidiary Mylan Pharmaceuticals has launched levalbuterol inhalation solution, 0.25%, (1.25mg/0.5ml). Mylan, which has already launched the product, will market this product with 180
Schering-Plough has introduced Claritin 12-Hour, the 12-hour allergy medicine found in the allergy aisle. New Claritin 12-Hour lasts all day and provides effective, non-drowsy relief from the worst
Gene Signal has reported the publication of interim results from a phase II study suggesting that the antisense oligonucleotide GS-101 is safe and effective at inhibiting and regressing
Pfizer has revealed latest findings based on a new post hoc sub-analysis of patients treated with Lipitor (atorvastatin calcium) in the five-year Treating to New Targets (TNT) study.
Oncolytics Biotech (Oncolytics) has reported that it has been granted its 32nd US Patent no 7582289, entitled ‘Viruses for the Treatment of Cellular Proliferative Disorders.’ The patent claims
SynCo Bio Partners has signed a contract to manufacture a live biotherapeutic with a Japanese pharmaceutical company. The undisclosed company’s product is a live biotherapeutic based anticancer drug.
Intrexon has purchased assets and operations of Avalon Pharmaceutical, a wholly-owned subsidiary of Clinical Data. As part of the transaction, Intrexon has purchased substantially all of the equipment
ACADIA has reported top-line results from the first pivotal phase III trial with pimavanserin in patients with Parkinson’s disease psychosis, or PDP. Reportedly, the study did not meet
PrimerDesign has launched a new test kit for detecting a new drug-resistant strain of the swine flu virus. The mutated virus has been identified in isolated cases in
Novavax has reported positive results from a phase II human clinical trial of its trivalent seasonal influenza virus-like particle (VLP) vaccine candidate. The vaccine was well tolerated and
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.